According to BioLineRx's latest financial reports the company has โน2.52 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | โน4.22 B | -0.6% |
2021-12-31 | โน4.25 B | 157.44% |
2020-12-31 | โน1.65 B | -15.73% |
2019-12-31 | โน1.96 B | -7.02% |
2018-12-31 | โน2.10 B | -33.27% |
2017-12-31 | โน3.15 B | 30.52% |
2016-12-31 | โน2.42 B | -23.57% |
2015-12-31 | โน3.16 B | 44.11% |
2014-12-31 | โน2.19 B | 95.29% |
2013-12-31 | โน1.12 B | -3.76% |
2012-12-31 | โน1.16 B | -14.87% |
2011-12-31 | โน1.37 B |